Search

Your search keyword '"Ivanyi, Philipp"' showing total 342 results
Start Over Author "Ivanyi, Philipp"
342 results on '"Ivanyi, Philipp"'

1. Valuing Vicinity: Memory attention framework for context-based semantic segmentation in histopathology

Author

Ester, Oliver, Hörst, Fabian, Seibold, Constantin, Keyl, Julius, Ting, Saskia, Vasileiadis, Nikolaos, Schmitz, Jessica, Ivanyi, Philipp, Grünwald, Viktor, Bräsen, Jan Hinrich, Egger, Jan, and Kleesiek, Jens

Subjects
Electrical Engineering and Systems Science - Image and Video Processing, Computer Science - Computer Vision and Pattern Recognition, Computer Science - Machine Learning
Abstract

The segmentation of histopathological whole slide images into tumourous and non-tumourous types of tissue is a challenging task that requires the consideration of both local and global spatial contexts to classify tumourous regions precisely. The identification of subtypes of tumour tissue complicates the issue as the sharpness of separation decreases and the pathologist's reasoning is even more guided by spatial context. However, the identification of detailed types of tissue is crucial for providing personalized cancer therapies. Due to the high resolution of whole slide images, existing semantic segmentation methods, restricted to isolated image sections, are incapable of processing context information beyond. To take a step towards better context comprehension, we propose a patch neighbour attention mechanism to query the neighbouring tissue context from a patch embedding memory bank and infuse context embeddings into bottleneck hidden feature maps. Our memory attention framework (MAF) mimics a pathologist's annotation procedure -- zooming out and considering surrounding tissue context. The framework can be integrated into any encoder-decoder segmentation method. We evaluate the MAF on a public breast cancer and an internal kidney cancer data set using famous segmentation models (U-Net, DeeplabV3) and demonstrate the superiority over other context-integrating algorithms -- achieving a substantial improvement of up to $17\%$ on Dice score. The code is publicly available at: https://github.com/tio-ikim/valuing-vicinity

Published
2022

5. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Author

Rischin, Danny, Hughes, Brett GM, Gao, Bo, McGrath, Margaret, Greil, Richard, Thurnher, Dietmar, Fuereder, Thorsten, Burian, Martin, Rottey, Sylvie, Machiels, Jean-Pascal, Clement, Paul M, Henry, Stéphanie, Deheneffe, Stéphanie, Vasconcelos Alves, Gustavo, Lima, Iane Pinto Figueiredo, Mourão Dias, Josiane, De Marchi, Pedro Rafael Martins, Mak, Milena Perez, Pereira de Santana Gomes, Andrea Juliana, Oliveira de Castro Junior, Dalvaro, Motta, Tatiane Cardoso, Agostinho Padoan, Monica Luciana, Victorina, Ana Paula, de Azevedo, Sergio Jobim, Siu, Lillian L, Brule, Stephanie, Hilton, John, Wang, Chang Shu, Bouganim, Nathaniel, Webster, Marc, Walker, John, Chua, Neil, Zambrano, Angela Regina, Quiroga Echeverri, Alicia, Niño Gomez, Oscar Mauricio, Ortiz, Carlos Alberto, Rojas, Luis, Cardona Zorilla, Andrés, Urrego Meléndez, Olga Marcela, Holečková, Petra Beran, Melichar, Bohuslav, Cvek, Jakub, Prausová, Jana, Vošmik, Milan, Delord, Jean-Pierre, Zasadny, Xavier, Geoffrois, Lionnel, Tao, Yungan, Pointreau, Yoann, Fietkau, Rainer, Haderlein, Marlen, Mueller, Andreas H, Schroeder, Ursula, Wollenberg, Barbara, Laban, Simon, Ivanyi, Philipp, Gruenwald, Viktor, Schafhausen, Philippe, Gutfeld, Orit, Gluck, Iris, Popovtzer, Aron, Meirovitz, Amichay, Billan, Salem, Brenner, Baruch, Limon, Dror, Licitra, Lisa, Perri, Francesco, Caponigro, Francesco, Violati, Martina, Ferrari, Daris, Nole, Franco, Bertolini, Federica, Livi, Lorenzo, Ghi, Maria Grazia, Imarisio, Ilaria, Tahara, Makoto, Homma, Akihiro, Ueda, Tsutomu, Asada, Yukinori, Yamazaki, Tomoko, Matsumoto, Koji, Fujii, Takashi, Ikeda, Sadakatsu, Takahashi, Shunji, Kinoshita, Takashi, Sasaki, Keita, Tsuji, Akihito, Ahn, Myung-Ju, Cho, Byoung Chul, Lee, Keun-Wook, Lee, Ki Hyeong, Choi, Moon Ki, Yun, Hwan Jung, Hendriks, Mathijs P, Oosting, Sjoukje F, Buter, Jan, Van Meerten, Esther, Graham, Jonathan, Kawecki, Andrzej, Debicka, Izabella, Maciejczyk, Adam, Pysz, Maciej, Filarska, Dorota, Hetnał, Marcin, Koralewski, Piotr, Wygoda, Andrzej, Składowski, Krzysztof, Talerczyk, Małgorzata, Berrocal Jaime, Alfonso, Pérez Segura, Pedro, Braña García, Irene, Basté Rotllan, Neus, Mesía Nin, Ricard, Taberna Sanz, Miren, Iglesias Docampo, Lara, Soria Rivas, Ainara, Rueda Domínguez, Antonio, Trigo Pérez, José Manuel, Hong, Ruey-Long, Li, Shau-Hsuan, Wang, Hung-Ming, Yen, Chia-Jui, Yang, Muh-Hwa, Chang, Yi-Fang, Liu, Yi-Chun, Lin, Jin-Ching, Ekenel, Meltem, Harputluoğlu, Hakan, Aksoy, Sercan, Özyilkan, Özgür, Bılıcı, Ahmet, Şendur, Mehmet Alı Nahıt, Arslan, Cagatay, Harrington, Kevin, Ramkumar, Shanmugasundaram, Gujral, Dorothy, Stewart, Simon, Powell, Melanie, Sibtain, Amen, Roques, Tom, Yip, Kent, Mirza, Arafat, Sivaramalingam, Muthiah, Belman, Neil D, Agarwala, Sanjiv, Anderson, Ian, Patel, Arpan, Maggiore, Ronald, Baumgart, Megan, Burtness, Barbara, Fidler, Mary Jo, Kaur, Varinder, Gaughan, Elizabeth, Worden, Francis, Rodriguez, Cristina P, Sukari, Ammar, Wong, Deborah, Yom, Sue, Walsh, William V, Fiorillo, Joseph A, Yorio, Jeffrey T, Obara, Grzegorz S, Alves, Gustavo, Hughes, Brett G M, Mesía, Ricard, Taberna, Miren, Waldron, John N, Simon, Christian, Grégoire, Vincent, Harrington, Kevin J, Swaby, Ramona F, Zhang, Yayan, Gumuscu, Burak, and Bidadi, Behzad

Published
2024
Full Text
View/download PDF

6. Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass)

Author

Grünwald, Viktor, Ivanyi, Philipp, Zschäbitz, Stefanie, Wirth, Manfred, Staib, Peter, Schostak, Martin, Dargatz, Philip, Müller, Lothar, Metz, Michael, Bergmann, Lothar, Steiner, Thomas, Welslau, Martin, Lorch, Anja, Rafiyan, Reza, Hellmis, Eva, Darr, Cristopher, Schütt, Philipp, Meiler, Johannes, Kretz, Thomas, Loidl, Wolfgang, Flörcken, Anne, Mänz, Martin, Hinke, Axel, Hartmann, Arndt, and Grüllich, Carsten

Published
2023
Full Text
View/download PDF

8. Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort

Author

Zschäbitz, Stefanie, Biernath, Nadine, Hilser, Thomas, Höllein, Alexander, Zengerling, Friedemann, Cascucelli, Jozefina, Paffenholz, Pia, Seidl, Daniel, Lutz, Christoph, Schlack, Katrin, Kingreen, Dorothea, Klümper, Niklas, Ivanyi, Philipp, von Amsberg, Gunhild, Heers, Hendrik, Roghmann, Florian, Tauber, Robert L., Cathomas, Richard, Hofer, Luisa, Niegisch, Günter, Klee, Melanie, Ehrenberg, Roland, Hassler, Andreas, Hadaschik, Boris A., Grünwald, Viktor, and Darr, Christopher

Published
2023
Full Text
View/download PDF

9. A post hoc analysis of the EPAZ trial: The role of geriatric variables in elderly soft tissue sarcoma patients on toxicity and outcome

Author

Hamacher, Rainer, Liu, Xiaofei, Schuler, Markus K., Hentschel, Leopold, Schöffski, Patrick, Kopp, Hans-Georg, Bauer, Sebastian, Kasper, Bernd, Lindner, Lars, Chemnitz, Jens-Markus, Crysandt, Martina, Stein, Alexander, Steffen, Björn, Richter, Stephan, Egerer, Gerlinde, Ivanyi, Philipp, Kunitz, Annegret, and Grünwald, Viktor

Published
2023
Full Text
View/download PDF

11. Characteristics of hospital admission during checkpoint-inhibition therapy.

Author

Fröhlich, Tabea Constanze, primary, Wiegmann, Jonas Paul, additional, Möhn, Nora, additional, Mahjoub, Susann, additional, Duzzi, Laura, additional, Narte, Emily, additional, Aurich, Johanna, additional, Berliner, Dominik, additional, Wirth, Thomas, additional, Golpon, Heiko, additional, von Wasielewski, Imke, additional, Heidel, Florian, additional, Skripuletz, Thomas, additional, Gutzmer, Ralf, additional, Beutel, Gernot, additional, and Ivanyi, Philipp, additional

Published
2024
Full Text
View/download PDF

14. Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project.

Author

Hilser, Thomas, Darr, Christopher, Niegisch, Günter, Schnabel, Marco Julius, Foller, Susan, Häuser, Lorine, Zschäbitz, Stefanie, Lewerich, Jonas, Ivanyi, Philipp, Schlack, Katrin, Paffenholz, Pia, Daetwyler, Eveline, Niedersüß-Beke, Dora, and Grünwald, Viktor

Subjects
THERAPEUTIC use of antineoplastic agents, THERAPEUTIC use of monoclonal antibodies, PATIENT safety, PROTEIN-tyrosine kinase inhibitors, TREATMENT effectiveness, RETROSPECTIVE studies, DESCRIPTIVE statistics, NEPHRECTOMY, METASTASIS, IMMUNE checkpoint inhibitors, KAPLAN-Meier estimator, RENAL cell carcinoma, DRUG efficacy, MEDICAL records, ACQUISITION of data, RESEARCH, NIVOLUMAB, DATA analysis software, SURVIVAL analysis (Biometry), PROGRESSION-free survival, CONFIDENCE intervals, DISEASE progression
Abstract

Simple Summary: ICI-based combinations have led to a significant change in mRCC medical treatment. However, data from real-world (RW) cohorts are rare. In this multicenter study, we evaluated the safety and effectiveness of cabozantinib plus nivolumab in real-world cohorts from centers in Germany, Switzerland, and Austria. The median PFS in the overall cohort was 18.6 months. We also analyzed subgroups in relation to the IMDC, histology, and with regard to the presence of bone metastasis. In summary, our real-word data support the promising efficacy data of the pivotal trials, particularly in patients with non-ccRCC and those without bone metastases at the start of the treatment. Introduction: Combinations of immune-checkpoint inhibitors (ICIs) are the standard of care (SOC) for treatment-naive metastatic renal cell carcinoma (mRCC) patients. In this multicenter study, we evaluated the RW safety and efficacy of cabozantinib plus nivolumab in mRCC patients. Methods: Data were retrospectively collected from twelve cancer centers in Germany, Switzerland, and Austria. Patients with advanced or mRCC were eligible. The investigator-based objective response rate (ORR) and progression free survival (PFS) were calculated from the start of the treatment to progression or death. Descriptive statistics and Kaplan–Meier (KM) plots were utilized where appropriate. Results: In total, 96 eligible patients (66.6% male) with a median age of 66.0 years were included. The most common histology was clear-cell RCC (ccRCC) in 63.4% (n = 61). A prior nephrectomy was performed in 60.4% (n = 58). ECOG 0-1 was 68.8% (n = 66). A partial response was documented in 43.8% of patients (n = 42), a stable disease in 32.3% (n = 31), and a progressive disease in 8.3% (n = 8) as the best overall response. Response data were not evaluable in 13.5% (n = 13). The median follow-up time was 12.7 months (95% CI, 10.0–15.3). The PFS rate at 6 months was 89.8% in the overall population (86.8% for ccRCC; 90.0% for non-ccRCC). Adverse events (AEs) were reported in 82.3% (n = 79) for all grades and 41.7% (n = 40) for grades 3–5. Elevated liver enzymes (34.4%), diarrhea (31.3%), and hand–foot syndrome (29.2%) were the three most frequent AEs of any grade and causality. Discussion/Conclusions: In this real-world cohort of mRCC patients, the application of cabozantinib plus nivolumab was shown to be safe and feasible. Our data support the use of cabozantinib plus nivolumab as a first-line standard therapy in mRCC patients. Major limitations were the retrospective data capture and short follow-up time of our study. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer

Author

Klümper, Niklas, primary, Tran, Ngoc Khanh, additional, Zschäbitz, Stefanie, additional, Hahn, Oliver, additional, Büttner, Thomas, additional, Roghmann, Florian, additional, Bolenz, Christian, additional, Zengerling, Friedemann, additional, Schwab, Constantin, additional, Nagy, Dora, additional, Toma, Marieta, additional, Kristiansen, Glen, additional, Heers, Hendrik, additional, Ivanyi, Philipp, additional, Niegisch, Günter, additional, Grunewald, Camilla Marisa, additional, Darr, Christopher, additional, Farid, Arian, additional, Schlack, Katrin, additional, Abbas, Mahmoud, additional, Aydogdu, Can, additional, Casuscelli, Jozefina, additional, Mokry, Theresa, additional, Mayr, Michael, additional, Niedersüß-Beke, Dora, additional, Rausch, Steffen, additional, Dietrich, Dimo, additional, Saal, Jonas, additional, Ellinger, Jörg, additional, Ritter, Manuel, additional, Alajati, Abdullah, additional, Kuppe, Christoph, additional, Meeks, Joshua, additional, Vera Badillo, Francisco E., additional, Nakauma-González, J. Alberto, additional, Boormans, Joost, additional, Junker, Kerstin, additional, Hartmann, Arndt, additional, Grünwald, Viktor, additional, Hölzel, Michael, additional, and Eckstein, Markus, additional

Published
2024
Full Text
View/download PDF

16. Die Weiterbildung „Medikamentöse Tumortherapie“ in deutschen HNO-Abteilungen – eine Umfrage der AG Onkologie der DGHNO

Author

Heil, Jule M., additional, Hoffmann, Thomas, additional, Sharma, Shachi Jenny, additional, Shabli, Sami, additional, Zech, Henrike, additional, Betz, Christian, additional, Wiegand, Susanne, additional, Dietz, Andreas, additional, Braun, Roman, additional, Wolf, Gregor, additional, Eichhorn, Sabine, additional, Park, Jonas, additional, Evers, Theo, additional, Tisch, Matthias, additional, Federspil, Philippe A., additional, Heidemann, Jan, additional, Hofmann, Veit M., additional, Herzog, Michael, additional, Kisser, Ulrich, additional, Abbaspour, Bektasch, additional, Thomas, Jan Peter, additional, Kürten, Cornelius, additional, Lang, Stephan, additional, Warnecke, Athanasia, additional, Lenarz, Thomas, additional, Ivanyi, Philipp, additional, Schapher, Mirco, additional, Traxdorf, Maximilian, additional, Döscher, Johannes, additional, Wollenberg, Barbara, additional, Wirth, Markus, additional, Klußmann, Jens Peter, additional, Theodoraki, Marie-Nicole, additional, and Laban, Simon, additional

Published
2024
Full Text
View/download PDF

17. Advanced training in systemic oncologic therapy in German Otorhinolaryngology departments – A survey of the DGHNO Oncology Working Group

Author

Heil, Jule M., additional, Hoffmann, Thomas, additional, Sharma, Shachi Jenny, additional, Shabli, Sami, additional, Zech, Henrike, additional, Betz, Christian, additional, Wiegand, Susanne, additional, Dietz, Andreas, additional, Braun, Roman, additional, Wolf, Gregor, additional, Eichhorn, Sabine, additional, Park, Jonas, additional, Evers, Theo, additional, Tisch, Matthias, additional, Federspil, Philippe A., additional, Heidemann, Jan, additional, Hofmann, Veit M., additional, Herzog, Michael, additional, Kisser, Ulrich, additional, Abbaspour, Bektasch, additional, Thomas, Jan Peter, additional, Kürten, Cornelius, additional, Lang, Stephan, additional, Warnecke, Athanasia, additional, Lenarz, Thomas, additional, Ivanyi, Philipp, additional, Schapher, Mirco, additional, Traxdorf, Maximilian, additional, Döscher, Johannes, additional, Wollenberg, Barbara, additional, Wirth, Markus, additional, Klußmann, Jens Peter, additional, Theodoraki, Marie-Nicole, additional, and Laban, Simon, additional

Published
2024
Full Text
View/download PDF

18. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Author

Machiels, Jean-Pascal, primary, Tao, Yungan, additional, Licitra, Lisa, additional, Burtness, Barbara, additional, Tahara, Makoto, additional, Rischin, Danny, additional, Alves, Gustavo, additional, Lima, Iane Pinto Figueiredo, additional, Hughes, Brett G M, additional, Pointreau, Yoann, additional, Aksoy, Sercan, additional, Laban, Simon, additional, Greil, Richard, additional, Burian, Martin, additional, Hetnał, Marcin, additional, Delord, Jean-Pierre, additional, Mesía, Ricard, additional, Taberna, Miren, additional, Waldron, John N, additional, Simon, Christian, additional, Grégoire, Vincent, additional, Harrington, Kevin J, additional, Swaby, Ramona F, additional, Zhang, Yayan, additional, Gumuscu, Burak, additional, Bidadi, Behzad, additional, Siu, Lillian L, additional, Hughes, Brett GM, additional, Gao, Bo, additional, McGrath, Margaret, additional, Thurnher, Dietmar, additional, Fuereder, Thorsten, additional, Rottey, Sylvie, additional, Machiels, Jean-Pascal, additional, Clement, Paul M, additional, Henry, Stéphanie, additional, Deheneffe, Stéphanie, additional, Vasconcelos Alves, Gustavo, additional, Mourão Dias, Josiane, additional, De Marchi, Pedro Rafael Martins, additional, Mak, Milena Perez, additional, Pereira de Santana Gomes, Andrea Juliana, additional, Oliveira de Castro Junior, Dalvaro, additional, Motta, Tatiane Cardoso, additional, Agostinho Padoan, Monica Luciana, additional, Victorina, Ana Paula, additional, de Azevedo, Sergio Jobim, additional, Brule, Stephanie, additional, Hilton, John, additional, Wang, Chang Shu, additional, Bouganim, Nathaniel, additional, Webster, Marc, additional, Walker, John, additional, Chua, Neil, additional, Zambrano, Angela Regina, additional, Quiroga Echeverri, Alicia, additional, Niño Gomez, Oscar Mauricio, additional, Ortiz, Carlos Alberto, additional, Rojas, Luis, additional, Cardona Zorilla, Andrés, additional, Urrego Meléndez, Olga Marcela, additional, Holečková, Petra Beran, additional, Melichar, Bohuslav, additional, Cvek, Jakub, additional, Prausová, Jana, additional, Vošmik, Milan, additional, Zasadny, Xavier, additional, Geoffrois, Lionnel, additional, Fietkau, Rainer, additional, Haderlein, Marlen, additional, Mueller, Andreas H, additional, Schroeder, Ursula, additional, Wollenberg, Barbara, additional, Ivanyi, Philipp, additional, Gruenwald, Viktor, additional, Schafhausen, Philippe, additional, Gutfeld, Orit, additional, Gluck, Iris, additional, Popovtzer, Aron, additional, Meirovitz, Amichay, additional, Billan, Salem, additional, Brenner, Baruch, additional, Limon, Dror, additional, Perri, Francesco, additional, Caponigro, Francesco, additional, Violati, Martina, additional, Ferrari, Daris, additional, Nole, Franco, additional, Bertolini, Federica, additional, Livi, Lorenzo, additional, Ghi, Maria Grazia, additional, Imarisio, Ilaria, additional, Homma, Akihiro, additional, Ueda, Tsutomu, additional, Asada, Yukinori, additional, Yamazaki, Tomoko, additional, Matsumoto, Koji, additional, Fujii, Takashi, additional, Ikeda, Sadakatsu, additional, Takahashi, Shunji, additional, Kinoshita, Takashi, additional, Sasaki, Keita, additional, Tsuji, Akihito, additional, Ahn, Myung-Ju, additional, Cho, Byoung Chul, additional, Lee, Keun-Wook, additional, Lee, Ki Hyeong, additional, Choi, Moon Ki, additional, Yun, Hwan Jung, additional, Hendriks, Mathijs P, additional, Oosting, Sjoukje F, additional, Buter, Jan, additional, Van Meerten, Esther, additional, Graham, Jonathan, additional, Kawecki, Andrzej, additional, Debicka, Izabella, additional, Maciejczyk, Adam, additional, Pysz, Maciej, additional, Filarska, Dorota, additional, Koralewski, Piotr, additional, Wygoda, Andrzej, additional, Składowski, Krzysztof, additional, Talerczyk, Małgorzata, additional, Berrocal Jaime, Alfonso, additional, Pérez Segura, Pedro, additional, Braña García, Irene, additional, Basté Rotllan, Neus, additional, Mesía Nin, Ricard, additional, Taberna Sanz, Miren, additional, Iglesias Docampo, Lara, additional, Soria Rivas, Ainara, additional, Rueda Domínguez, Antonio, additional, Trigo Pérez, José Manuel, additional, Hong, Ruey-Long, additional, Li, Shau-Hsuan, additional, Wang, Hung-Ming, additional, Yen, Chia-Jui, additional, Yang, Muh-Hwa, additional, Chang, Yi-Fang, additional, Liu, Yi-Chun, additional, Lin, Jin-Ching, additional, Ekenel, Meltem, additional, Harputluoğlu, Hakan, additional, Özyilkan, Özgür, additional, Bılıcı, Ahmet, additional, Şendur, Mehmet Alı Nahıt, additional, Arslan, Cagatay, additional, Harrington, Kevin, additional, Ramkumar, Shanmugasundaram, additional, Gujral, Dorothy, additional, Stewart, Simon, additional, Powell, Melanie, additional, Sibtain, Amen, additional, Roques, Tom, additional, Yip, Kent, additional, Mirza, Arafat, additional, Sivaramalingam, Muthiah, additional, Belman, Neil D, additional, Agarwala, Sanjiv, additional, Anderson, Ian, additional, Patel, Arpan, additional, Maggiore, Ronald, additional, Baumgart, Megan, additional, Fidler, Mary Jo, additional, Kaur, Varinder, additional, Gaughan, Elizabeth, additional, Worden, Francis, additional, Rodriguez, Cristina P, additional, Sukari, Ammar, additional, Wong, Deborah, additional, Yom, Sue, additional, Walsh, William V, additional, Fiorillo, Joseph A, additional, Yorio, Jeffrey T, additional, and Obara, Grzegorz S, additional

Published
2024
Full Text
View/download PDF

20. Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study

Author

Erlmeier, Franziska, Steffens, Sandra, Stöhr, Christine, Herrmann, Edwin, Polifka, Iris, Agaimy, Abbas, Trojan, Lutz, Ströbel, Philipp, Becker, Frank, Wülfing, Christian, Barth, Peter, Stöckle, Michael, Staehler, Michael, Stief, Christian, Haferkamp, Axel, Hohenfellner, Markus, Macher-Göppinger, Stephan, Wullich, Bernd, Noldus, Joachim, Brenner, Walburgis, Roos, Frederik C., Walter, Bernhard, Otto, Wolfgang, Burger, Maximilian, Schrader, Andres Jan, Hartmann, Arndt, and Ivanyi, Philipp

Published
2021
Full Text
View/download PDF

22. Diagnostik und Therapie von Tumoren mit NTRK-Genfusionen

Author

Stenzinger, Albrecht, van Tilburg, Cornelis M., Tabatabai, Ghazaleh, Länger, Florian, Graf, Norbert, Griesinger, Frank, Heukamp, Lukas C., Hummel, Michael, Klingebiel, Thomas, Hettmer, Simone, Vokuhl, Christian, Merkelbach-Bruse, Sabine, Overkamp, Friedrich, Reichardt, Peter, Scheer, Monika, Weichert, Wilko, Westphalen, C. Benedikt, Bokemeyer, Carsten, Ivanyi, Philipp, Loges, Sonja, Schirmacher, Peter, Wörmann, Bernhard, Bielack, Stefan, and Seufferlein, Thomas T. W.

Published
2021
Full Text
View/download PDF

24. Bevacizumab-associated glomerular microangiopathy

Author

Person, Fermin, Rinschen, Markus M., Brix, Silke R., Wulf, Sonia, Noriega, Maria de las Mercedes, Fehrle, Wilfried, Schmitz, Jessica, Schwarz, Anke, Ivanyi, Philipp, Steinmetz, Oliver M., Reinhard, Linda, Hoxha, Elion, Zipfel, Peter F., Bräsen, Jan Hinrich, and Wiech, Thorsten

Published
2019
Full Text
View/download PDF

26. Mit Hilfe der körpereigenen Abwehr gegen Krebs

Author

Ivanyi, Philipp

Subjects
Krebstherapie, CAR-T-Zell-Therapie, Im Fokus, Immun-Checkpoint-Inhibition, Immunonkologie
Abstract

Immunonkologische Therapien helfen, die körpereigene Immunantwort gezielt auf Tumorzellen auszurichten und Krebserkrankungen zu behandeln. Eine besondere Rolle kommt den zytotoxischen T-Lymphozyten zu, die strengen Regulationsmechanismen unterliegen. Diese Regulation durch Immun-Checkpoints nutzen immunonkologische Wirkstoffe und aktivieren auf diesem Weg die T-Lymphozyten für den Angriff auf Krebszellen. Ein weiterer immunonkologischer Ansatz ist die Zelltherapie, die patienteneigene T-Lymphozyten genetisch modifiziert und so ein gezieltes Erkennen von Krebszellen und deren Bekämpfung ermöglicht. Darüber hinaus bietet die Immunonkologie weitere Möglichkeiten, wie etwa eine allgemeine Immunstimulation über Zytokine, Impfstoffe gegen Krebs oder onkolytische Viren. Die Immunonkologie ist Gegenstand intensiver Forschungsarbeit und klinischer Entwicklung. Neue Wirkstoffe sowie Kombinationsansätze helfen dabei, die Versorgung von Krebspatienten weiter zu verbessern., Immuno-oncological therapies help to direct the body’s immune response specifically towards tumour cells. Cytotoxic T lymphocytes which play a crucial role for such therapies are subject to strict regulatory mechanisms. This regulation by immune checkpoints is used by immuno-oncological drugs in order to activate T lymphocytes and allow them to attack cancer cells. Another immuno-oncological approach is cell therapy, where the patient’s T lymphocytes are genetically modified to specifically recognize and fight tumour cells. In addition, immuno-oncology offers other options, such as general immune stimulation via cytokines, vaccines against cancer or oncolytic viruses. Immuno-oncology is the subject of intense research and clinical development. New drugs and combination approaches help to further improve the treatment of cancer patients.

Published
2022

29. Occurrence of NECTIN4 amplification in solid tumors and enfortumab vedotin response in metastatic urothelial cancer.

Author

Klümper, Niklas, Tran, Ngoc Khanh, Zschaebitz, Stefanie, Hahn, Oliver, Zengerling, Friedemann, Nagy, Dora, Kristiansen, Glen, Ivanyi, Philipp, Grunewald, Camilla Marisa, Darr, Christopher, Schlack, Katrin, Rausch, Steffen, Ritter, Manuel, Junker, Kerstin, Hartmann, Arndt, Grünwald, Viktor, Hölzel, Michael, and Eckstein, Markus

Published
2024
Full Text
View/download PDF

32. Real-world outcomes of patients with operable renal cell carcinoma from the German translational cancer research consortium (DKTK) network.

Author

Grünwald, Viktor, Thomas, Christian, De Santis, Maria, Gratzke, Christian, Chun, Felix, Mager, Rene, Retz, Margitta, Von Amsberg, Gunhild, Ivanyi, Philipp, Christian, Bolenz, Kübler, Hubert, Hadaschik, Boris A., Hahn, Svenja, Erhard, Ian, Reiter, Bastian, Lablans, Martin, Vehreschild, Janne, Brucker, Daniel, and Maier, Daniel

Published
2024
Full Text
View/download PDF

33. Real world evidence from a retrospective multi-center analysis on first-line therapy for metastatic renal cell carcinoma with non-clear cell and/or sarcomatoid histologies.

Author

Paffenholz, Pia, Zschaebitz, Stefanie, Casuscelli, Jozefina, Rinderknecht, Emily, Mattigk, Angelika, Gür, Melis, Ivanyi, Philipp, Hilser, Thomas, Darr, Christopher, Mandal, Subhajit, Schlack, Katrin, Seidl, Daniel, Handke, Analena, Klee, Melanie, Nestler, Tim, Rehlinghaus, Marc, Hijazi, Sameh, Heidenreich, Axel, Grünwald, Viktor, and Schostak, Martin

Published
2024
Full Text
View/download PDF

34. Treatment options and outcome of patients with metastatic renal cell carcinoma with brain or bone metastases: Real world evidence from a German retrospective multi-center analysis.

Author

Paffenholz, Pia, Ivanyi, Philipp, Casuscelli, Jozefina, Stelmach, Ramona, Guer, Melis, Schlack, Katrin, Darr, Christopher, Rinderknecht, Emily, Hilser, Thomas, Flegar, Luka, Klee, Melanie, Seidl, Daniel, Handke, Analena, Nestler, Tim, Mattigk, Angelika, Augustin, Marinela, Hijazi, Sameh, Rehlinghaus, Marc, Heidenreich, Axel, and Gruenwald, Viktor

Published
2024
Full Text
View/download PDF

37. Nivoswitch trial: Predictive value of PD-L1 in plasma and extracellular vesicles.

Author

Sonnleithner, JAdzia, primary, Himbert, Dirk, additional, Zeuschner, Philip, additional, Hartmann, Arndt, additional, Grüllich, Carsten, additional, Ivanyi, Philipp, additional, Wirth, Manfred, additional, Staib, Peter, additional, Schostak, Martin, additional, Dargatz, Philip, additional, Müller, Lothar, additional, Grünwald, Viktor, additional, and Junker, Kerstin, additional

Published
2023
Full Text
View/download PDF

38. Cabozantinib + nivolumab in adult patients with advanced or metastatic renal cell carcinoma: A retrospective, non-interventional study in a real-world cohort.

Author

Hilser, Thomas, primary, Darr, Christopher, additional, Niegisch, Guenter, additional, Schnabel, Marco Julius, additional, Foller, Susan, additional, Haeuser, Lorine, additional, Zschaebitz, Stefanie, additional, Lewerich, Jonas, additional, Anders-Meyn, Merle, additional, Ivanyi, Philipp, additional, Schlack, Katrin, additional, and Grünwald, Viktor, additional

Published
2023
Full Text
View/download PDF

42. Kampf der Zellen

Author

Ivanyi, Philipp

Abstract

Immunonkologische Therapien helfen, die körpereigene Immunantwort gezielt auf Tumorzellen auszurichten und Krebserkrankungen zu behandeln. Eine besondere Rolle kommt den zytotoxischen T-Lymphozyten zu, die strengen Regulationsmechanismen unterliegen. Diese Regulation durch Immun-Checkpoints nutzen immunonkologische Wirkstoffe und aktivieren auf diesem Weg die T-Lymphozyten für den Angriff auf Krebszellen. Ein weiterer immunonkologischer Ansatz ist die Zelltherapie, die patienteneigene T-Lymphozyten genetisch modifiziert und so ein gezieltes Erkennen von Krebszellen und deren Bekämpfung ermöglicht. Darüber hinaus bietet die Immunonkologie weitere Möglichkeiten, wie etwa eine allgemeine Immunstimulation über Zytokine, Impfstoffe gegen Krebs oder onkolytische Viren. Die Immunonkologie ist Gegenstand intensiver Forschungsarbeit und klinischer Entwicklung. Neue Wirkstoffe sowie Kombinationsansätze helfen dabei, die Versorgung von Krebspatienten weiter zu verbessern., Biologie in unserer Zeit, Early View

Published
2022
Full Text
View/download PDF

44. Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Prospective, Multicenter, Phase IV Trial

Author

Grünwald, Viktor, primary, Pink, Daniel, additional, Egerer, Gerlinde, additional, Schalk, Enrico, additional, Augustin, Marinela, additional, Deinzer, Christoph K. W., additional, Kob, Viola, additional, Reichert, Dietmar, additional, Kebenko, Maxim, additional, Brandl, Stephan, additional, Hahn, Dennis, additional, Lindner, Lars H., additional, Hoiczyk, Mathias, additional, Ringsdorf, Uta, additional, Hanker, Lars C., additional, Hempel, Dirk, additional, De Rivas, Beatriz, additional, Wismann, Tobias, additional, and Ivanyi, Philipp, additional

Published
2022
Full Text
View/download PDF

48. Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor‐associated neurotoxicity.

Author

Möhn, Nora, Mahjoub, Susann, Duzzi, Laura, Narten, Emily, Grote‐Levi, Lea, Körner, Gudrun, Seeliger, Tabea, Beutel, Gernot, Bollmann, Benjamin‐Alexander, Wirth, Thomas, Huss, André, Tumani, Hayrettin, Grimmelmann, Imke, Gutzmer, Ralf, Ivanyi, Philipp, and Skripuletz, Thomas

Subjects
MONOCYTE chemotactic factor, IMMUNE checkpoint proteins, DRUG side effects, IPILIMUMAB, BRAIN-derived neurotrophic factor, IMMUNE checkpoint inhibitors, MONOCLONAL gammopathies
Abstract

Background: Oncological patients can benefit substantially from treatment with immune checkpoint inhibitors (ICI). However, there is a growing awareness of immune‐related adverse events (irAE). Especially ICI‐mediated neurological adverse events (nAE(+)), are tough to diagnose and biomarkers to identify patients at risk are missing. Methods: A prospective register with prespecified examinations was established for ICI treated patients in December 2019. At the time of data cut‐off, 110 patients were enrolled and completed the clinical protocol. Herein, cytokines and serum neurofilament light chain (sNFL) from 21 patients were analyzed. Results: nAE of any grade were observed in 31% of the patients (n = 34/110). In nAE(+) patients a significant increase in sNFL concentrations over time was observed. Patients with higher‐grade nAE had significantly elevated serum‐concentrations of monocyte chemoattractant protein 1 (MCP‐1) and brain‐derived neurotrophic factor (BDNF) at baseline compared to individuals without any nAE (p < 0.01 and p < 0.05). Conclusion: Here, we identified nAE to occur more frequently than previously reported. Increase of sNFL during nAE confirms the clinical diagnosis of neurotoxicity and might be a suitable marker for neuronal damage associated with ICI therapy. Furthermore, MCP‐1 and BDNF are potentially the first clinical‐class nAE predictors for patients under ICI therapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. cMET: a prognostic marker in papillary renal cell carcinoma?

Author

Erlmeier, Franziska, primary, Bruecher, Benedict, additional, Stöhr, Christine, additional, Herrmann, Edwin, additional, Polifka, Iris, additional, Agaimy, Abbas, additional, Trojan, Lutz, additional, Ströbel, Philipp, additional, Becker, Frank, additional, Wülfing, Christian, additional, Barth, Peter, additional, Stöckle, Michael, additional, Staehler, Michael, additional, Stief, Christian, additional, Haferkamp, Axel, additional, Hohenfellner, Markus, additional, Macher-Göppinger, Stephan, additional, Wullich, Bernd, additional, Noldus, Joachim, additional, Brenner, Walburgis, additional, Roos, Frederik C., additional, Walter, Bernhard, additional, Otto, Wolfgang, additional, Burger, Maximilian, additional, Schrader, Andres Jan, additional, Hartmann, Arndt, additional, Mondorf, Yvonne, additional, Ivanyi, Philipp, additional, Mikuteit, Marie, additional, and Steffens, Sandra, additional

Published
2022
Full Text
View/download PDF

50. Final analysis of a non-interventional study on cabozantinib in patients with advanced renal cell carcinoma after prior checkpoint inhibitor therapy (CaboCHECK).

Author

Grünwald, Viktor, primary, Boegemann, Martin, additional, Rafiyan, Mohammad-Reza, additional, Niegisch, Guenter, additional, Schnabel, Marco Julius, additional, Flörcken, Anne, additional, Maasberg, Michael, additional, Maintz, Christoph, additional, Zahn, Mark-Oliver, additional, Wortmann, Anke, additional, Hinkel, Andreas, additional, Casper, Jochen, additional, Darr, Christopher, additional, Hilser, Thomas, additional, Schulze, Matthias, additional, Sookthai, Disorn, additional, Schoenherr, Caroline, additional, and Ivanyi, Philipp, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results